John E. Imhoff - 17 Jul 2023 Form 4 Insider Report for GUIDED THERAPEUTICS INC (GTHP)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: GTHP
Reported as of: 17 Jul 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Sep 2023, 15:53:16 UTC
Prior SEC filing: 26 Jun 2023
Next SEC filing: 22 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ John E. Imhoff

Key filing fact

John E. Imhoff filed Form 4 for GUIDED THERAPEUTICS INC (GTHP) on 07 Sep 2023.

Key facts

This page summarizes John E. Imhoff's Form 4 filing for GUIDED THERAPEUTICS INC (GTHP).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Sep 2023, 15:53.

Change

Previous filing in this sequence was filed on 26 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GTHP transaction

Common Stock

Other

Transaction value
Shares: +26,301
Change %: +0.6%
Price
Shares after: 4,436,637
Date: 17 Jul 2023
Ownership: Direct
Footnotes: F1

GTHP transaction

Common Stock

Purchase

Transaction value
Shares: +500,899
Change %: +11%
Price
Shares after: 4,937,536
Date: 11 Aug 2023
Ownership: Direct
Footnotes: F2

GTHP transaction

Common Stock

Other

Transaction value
Shares: +112,568
Change %: +2.3%
Price
Shares after: 5,050,104
Date: 21 Aug 2023
Ownership: Direct
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GTHP transaction Derivative

Series E Preferred Stock

Purchase

Transaction value
Shares: +250
Change %
Price
Shares after: 250
Date: 11 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,000,000
Exercise price: $0.2500
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2139.

Footnote F2

These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3)).

Footnote F3

These securities consist of Series E Convertible Preferred Stock ("Series E Preferred") of the Issuer that are presently convertible on a 1-for-4,000 basis into Common Stock without payment or further consideration. The Series E Preferred shares are convertible at any time until 8/21/2025. The Series E Preferred has no expiration date.

Footnote F4

These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1777.